Trial Profile
Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sanofi
- 18 Sep 2014 New trial record